NASDAQ$GERN
Geron Corp · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2020.
Geron Corporation reported a net loss of $19.7 million, or $0.06 per share, for the third quarter of 2020. As of September 30, 2020, the company had approximately $274 million in cash and investments, which is expected to be sufficient for operations until the end of 2022.
- Advanced enrollment in the ongoing IMerge Phase 3 clinical trial and start-up activities for the upcoming Phase 3 clinical trial in refractory myelofibrosis (IMpactMF).
- Secured European orphan drug designation in lower risk MDS.
- Received acceptance for presentation of all ten abstracts submitted to the ASH Annual Meeting.
- Strengthened balance sheet with a loan facility providing additional financial flexibility.
Headline financials
Revenue & EPS history
Geron · Revenue · Quarterly
$108K
Revenue by segment
Geron · $164K total across 1 segment · Q3 2023
- Royalties$164K—100.0%
Forward guidance
Geron expects its 2020 operating expense burn to range from $70 to $75 million. Enrollment in the IMerge Phase 3 trial is expected to be complete in the second quarter of 2021, with top-line results available in the second half of 2022. The IMpactMF Phase 3 clinical trial is expected to be open for screening and enrollment in the first quarter of 2021.
Tailwinds
- IMpactMF will be open for screening and enrollment in the first quarter of 2021.
- The loan facility is available through the end of 2022 subject to the achievement of certain clinical, financial and regulatory milestones.
- Top-line results for IMerge will be available in the second half of 2022.
- Almost all of the new IMerge sites will be open for screening and enrollment by the end of 2020.
- Under current planning assumptions, for IMpactMF Geron expects to complete patient enrollment in the second half of 2022, conduct an interim analysis in the first half of 2023 and conduct a final analysis in the first half of 2024.
Headwinds
- The recent resurgence of the COVID-19 pandemic is causing an uncertain and unpredictable impact on clinical trial activities.
- The trial will most likely be fully enrolled in the second quarter of 2021.
- The anticipated timing is subject to potential delays or interruptions associated with the evolving effects of the ongoing COVID-19 pandemic, which causes unpredictability when projecting future enrollment trends.
- Geron will need to raise substantial capital in order to complete the development and commercialization of imetelstat.
- Whether there are failures or delays in manufacturing sufficient quantities of imetelstat or other clinical trial materials in a timely manner, whether due to the current or evolving effects of the COVID-19 pandemic or otherwise.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+0.6%
Avg return
Earnings day
-1.3%
Avg return
5 days after
+4.2%
Avg return
30 days after
42%
27 / 64 earnings
Positive
+35.3%
Q4 2013
Best reaction
-32.1%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.2% | -15.8% | -29.1% | |
| Q4 2025 | -11.3% | -20.5% | -28.2% | |
| Q3 2025 | -4.5% | +0.9% | +13.9% | |
| Q1 2025 | -0.8% | -3.0% | +21.2% | |
| Q4 2024 | -32.1% | -27.8% | -30.4% | |
| Q3 2024 | -0.5% | -7.0% | -8.0% | |
| Q2 2024 | +3.1% | +0.2% | -6.8% | |
| Q1 2024 | -3.7% | -5.1% | -13.0% | |
| Q4 2023 | -3.4% | +0.5% | +59.4% | |
| Q3 2023 | +2.6% | -1.0% | +3.1% | |
| Q2 2023 | -7.5% | -7.5% | -22.5% | |
| Q1 2023 | +9.9% | +6.0% | +27.7% | |
| Q4 2022 | -3.4% | -10.7% | -24.8% | |
| Q3 2022 | -2.3% | +0.9% | +7.0% | |
| Q2 2022 | +8.3% | +2.3% | +22.1% | |
| Q1 2022 | +13.8% | +11.5% | +8.5% | |
| Q4 2021 | +0.9% | -3.7% | +46.3% | |
| Q3 2021 | -9.3% | -8.7% | -21.5% | |
| Q2 2021 | +4.9% | +4.1% | +11.5% | |
| Q1 2021 | +4.5% | +7.5% | +12.8% | |
| Q4 2020 | -6.0% | -3.3% | -19.1% | |
| Q3 2020 | -4.8% | -0.5% | -2.7% | |
| Q2 2020 | -2.3% | -7.0% | +6.4% | |
| Q1 2020 | -1.8% | +0.0% | +17.7% | |
| Q4 2019 | -6.8% | -7.8% | +7.8% | |
| Q3 2019 | +0.7% | +0.0% | +2.0% | |
| Q2 2019 | -3.3% | -0.8% | +16.7% | |
| Q1 2019 | -0.6% | -3.3% | -19.9% | |
| Q4 2018 | +0.7% | +7.7% | +27.3% | |
| Q3 2018 | +9.2% | +7.8% | +5.2% | |
| Q2 2018 | +4.5% | +4.8% | +63.6% | |
| Q1 2018 | -9.9% | -10.9% | -2.1% | |
| Q4 2017 | +24.7% | +43.4% | +10.6% | |
| Q3 2017 | -8.9% | -8.4% | -14.2% | |
| Q2 2017 | -7.1% | -8.4% | -5.8% | |
| Q1 2017 | +0.8% | +11.7% | +4.7% | |
| Q4 2016 | +2.3% | -0.9% | +5.6% | |
| Q3 2016 | +2.7% | +2.2% | +8.6% | |
| Q2 2016 | -0.4% | +0.0% | +1.1% | |
| Q1 2016 | -2.2% | — | — | |
| Q4 2015 | -4.2% | — | — | |
| Q3 2015 | +3.4% | — | — | |
| Q2 2015 | -7.8% | — | — | |
| Q1 2015 | +3.1% | — | — | |
| Q4 2014 | -7.0% | — | — | |
| Q3 2014 | +20.2% | — | — | |
| Q2 2014 | -5.3% | — | — | |
| Q1 2014 | -6.4% | — | — | |
| Q4 2013 | +35.3% | — | — | |
| Q3 2013 | +28.2% | — | — | |
| Q2 2013 | +14.6% | — | — | |
| Q1 2013 | -1.8% | — | — | |
| Q4 2012 | -5.1% | — | — | |
| Q3 2012 | -1.5% | — | — | |
| Q2 2012 | +3.8% | — | — | |
| Q1 2012 | -0.7% | — | — | |
| Q4 2011 | -0.6% | — | — | |
| Q3 2011 | +4.2% | — | — | |
| Q2 2011 | -15.6% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | +1.7% | — | — | |
| Q3 2010 | -4.5% | — | — | |
| Q2 2010 | +26.4% | — | — | |
| Q1 2010 | +3.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro